Abstract
Radiotherapy is one of the important treatment strategies for patients with advanced hepatocellular carcinomas. Developing novel sensitizers for radiotherapy is a key issue due to the low intrinsic radiosensitivity of hepatocellular carcinomas. It was reported the wild-type NBS1 inhibitory peptide (wtNIP) can increase radiosensitivity in several cancer cell lines by abrogating ATM-NBS1 interaction and interrupting cellular DNA damage response. Here, we developed a novel NGRconjugated peptide (NGR-sR9-wtNIP) through coupling the CNGRC angiogenic vessel-homing peptide NGR with the wtNIP peptide. Fusion peptide was tested for internalization, cytotoxicity in Hep3B cells and for tumor localization, and for toxicity in nude mice bearing human hepatocellular carcinomas xenografts. The radiosensitizing activity of NGR-sR9-wtNIP was investigated as well. We found that NGR-sR9-wtNIP can inhibit irradiation induced NBS1 phosphorylation and induce radiosensitization in Hep3B cells. When combined with IR, NGR-sR9-wtNIP suppressed tumor growth obviously in xenograft mice. In addition, the fusion peptide localized in tumor tissue specifically and barely led to any side effects on mice. Taken together, our data strongly suggest that NGRsR9- wtNIP has radiosensitizing potential for radiotherapy of hepatocellular carcinomas.
Keywords: DNA damage responses, NGR, irradiation, NIP (NBS1 inhibitory peptide), radiosensitization.
Current Cancer Drug Targets
Title:A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Volume: 15 Issue: 6
Author(s): Jinlu Ma, Dan Zhang, Xia Ying, Ying Zhao, Chenchen He, Qing Zhu and Suxia Han
Affiliation:
Keywords: DNA damage responses, NGR, irradiation, NIP (NBS1 inhibitory peptide), radiosensitization.
Abstract: Radiotherapy is one of the important treatment strategies for patients with advanced hepatocellular carcinomas. Developing novel sensitizers for radiotherapy is a key issue due to the low intrinsic radiosensitivity of hepatocellular carcinomas. It was reported the wild-type NBS1 inhibitory peptide (wtNIP) can increase radiosensitivity in several cancer cell lines by abrogating ATM-NBS1 interaction and interrupting cellular DNA damage response. Here, we developed a novel NGRconjugated peptide (NGR-sR9-wtNIP) through coupling the CNGRC angiogenic vessel-homing peptide NGR with the wtNIP peptide. Fusion peptide was tested for internalization, cytotoxicity in Hep3B cells and for tumor localization, and for toxicity in nude mice bearing human hepatocellular carcinomas xenografts. The radiosensitizing activity of NGR-sR9-wtNIP was investigated as well. We found that NGR-sR9-wtNIP can inhibit irradiation induced NBS1 phosphorylation and induce radiosensitization in Hep3B cells. When combined with IR, NGR-sR9-wtNIP suppressed tumor growth obviously in xenograft mice. In addition, the fusion peptide localized in tumor tissue specifically and barely led to any side effects on mice. Taken together, our data strongly suggest that NGRsR9- wtNIP has radiosensitizing potential for radiotherapy of hepatocellular carcinomas.
Export Options
About this article
Cite this article as:
Ma Jinlu, Zhang Dan, Ying Xia, Zhao Ying, He Chenchen, Zhu Qing and Han Suxia, A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization, Current Cancer Drug Targets 2015; 15 (6) . https://dx.doi.org/10.2174/1568009615666150408114817
DOI https://dx.doi.org/10.2174/1568009615666150408114817 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The TWEAK-Fn14 System: Breaking the Silence of Cytokine-Induced Skeletal Muscle Wasting
Current Molecular Medicine Expression of Opioid Receptors During Peripheral Inflammation
Current Topics in Medicinal Chemistry Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo
Current Cancer Drug Targets Editorial [Hot Topic: Designing New Drugs For High Grade Gliomas (Executive Guest Editor: Guido Frosina)]
Current Pharmaceutical Design Editorial [Hot Topic: Angiogenesis Agents (Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design The Past, Current Studies and Future of Organometallic <sup>99m</sup>Tc(CO)3 Labeled Peptides and Proteins
Current Pharmaceutical Design Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Development and Current Status of Unconventional Platinum Anticancer Complexes
Mini-Reviews in Medicinal Chemistry The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
Recent Patents on Anti-Cancer Drug Discovery Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Rational Design of 5-Aminolevulinic Acid Derivatives Aimed at Improving Photodynamic Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Nanomedical Applications of Amphiphilic Dendrimeric Micelles
Current Medicinal Chemistry Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types
Current Gene Therapy The Role of microRNAs in Gliomas – Therapeutic Implications
Current Molecular Pharmacology Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Editorial :
Recent Patents on CNS Drug Discovery (Discontinued)